Cancer Cytopathology最新文献

{"title":"Utility of an anchored multiplex polymerase chain reaction-based fusion assay for diagnosis of soft tissue tumors in cytology","authors":"T. Leif Helland MD,&nbsp;Adam S. Fisch MD, PhD,&nbsp;Ivan Chebib MD","doi":"10.1002/cncy.22881","DOIUrl":"10.1002/cncy.22881","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Fine-needle aspiration specimens from soft tissue tumors are complicated by lack of tissue architecture and limited material for ancillary testing. There are little data on the feasibility of next-generation sequencing techniques for fusion detection on soft tissue cytology specimens. This study explored the role of an anchored multiplex polymerase chain reaction (PCR)-based gene fusion assay in aiding the diagnosis of mesenchymal neoplasms on cytology samples.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The laboratory information system was queried for cytology specimens that had undergone testing by anchored multiplex PCR. After exclusion of epithelial and hematolymphoid neoplasms, clinical and pathologic information was collected on the remaining cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 1609 cytology specimens tested with anchored multiplex PCR. Of these, 48 (3%) were cytology specimens from mesenchymal tumors. Anchored multiplex PCR was positive for a reportable fusion transcript in 14 of 48 cases (29%); there was no fusion detected in 32 cases (67%), and there was insufficient tissue for analysis in two cases (4%). The detectable fusion partners included <i>ALK</i> (<i>n</i> = 4), <i>STAT6</i> (<i>n</i> = 4), <i>EWSR1</i> (<i>n</i> = 3), and one each of <i>SS18</i>, <i>YAP1</i>, and <i>PHF1</i>. Of the cases in which a fusion partner was detected, eight of 14 were disease-defining on cytology preparation, and six of 14 provided molecular confirmation of a metastatic focus of a previously diagnosed tumor.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The anchored, multiplex PCR-based gene fusion assay is a powerful orthogonal tool in helping diagnose mesenchymal neoplasms on cytology specimens. The material obtained for cytologic analysis yields sufficient quality/quantity of tissue in the majority of cases tested.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 9","pages":"580-587"},"PeriodicalIF":2.6,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of malignancy and overall survival associated with the diagnostic categories in the World Health Organization Reporting System for Pancreaticobiliary Cytopathology","authors":"Wen-Yu Hsiao MD, PhD,&nbsp;Qun Wang MD, PhD","doi":"10.1002/cncy.22880","DOIUrl":"10.1002/cncy.22880","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The World Health Organization (WHO) classification system revised the Papanicolaou Society of Cytopathology (PSC) system for reporting pancreaticobiliary cytopathology. To better stratify intraductal and/or cystic neoplasms by cytologic grade, the <i>neoplastic, other</i> category was replaced by two new categories: <i>pancreaticobiliary neoplasm, low-risk/grade</i> <i>(PaN-Low)</i> and <i>pancreaticobiliary neoplasm, high-risk/grade</i> <i>(PaN-High)</i>. Low-grade malignancies were placed in the <i>malignant</i> category, and benign neoplasms were placed in the <i>benign/negative for malignancy</i> category.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An institutional pathology database search identified patients who underwent endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for pancreatic lesions from January 2015 to April 2022. The absolute risk of malignancy (ROM) was determined by histologic and/or clinical follow-up of at least 6 months, and overall survival rates were calculated across diagnostic categories, comparing the WHO and PSC systems.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 1012 cases were reviewed and recategorized. The ROM for the WHO system was 8.3% for <i>insufficient/inadequate/nondiagnostic</i>, 3.2% for <i>benign/negative for malignancy</i>, 24.6% for <i>atypical</i>, 9.1% for <i>PaN-Low</i>, 46.7% for <i>PaN-High</i>, 75% for <i>suspicious for malignancy</i>, and 100% for <i>malignant</i>. Comparatively, the ROM for the PSC system was 7.4% for <i>nondiagnostic</i>, 3.0% for <i>negative for malignancy</i>, 23.1% for <i>atypical</i>, 0% for <i>neoplastic, benign</i>, 7.3% for <i>neoplastic, other</i>, 75% for <i>suspicious for malignancy</i>, and 100% for <i>malignant</i>. The WHO system demonstrated superior stratification for overall survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The WHO system significantly improves the stratification of ROM and overall survival across diagnostic categories by introducing the <i>PaN-Low</i> and <i>PaN-High</i> categories and reassigning low-grade malignancies to the <i>malignant</i> category. Analyzing EUS-FNA samples with the WHO system provides critical insights for guiding clinical management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 10","pages":"635-645"},"PeriodicalIF":2.6,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid on-site evaluation of FNA biopsies and rapid interpretation of core biopsy touch preparation slides: Correct utilization of current procedural terminology codes","authors":"Swati Mehrotra MD,&nbsp;Carol A. Filomena MD","doi":"10.1002/cncy.22878","DOIUrl":"10.1002/cncy.22878","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 12","pages":"741-744"},"PeriodicalIF":2.6,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141549355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The negative outlook: Long-term follow up of ThyroSeq negative and low-risk nodules","authors":"Raquel A. Perry BS,&nbsp;Megan F. Lee MD,&nbsp;Rachel C. Jug MB, BCh, BAO,&nbsp;Rajesh C. Dash MD,&nbsp;Daniel J. Rocke MD, JD,&nbsp;Xiaoyin “Sara” Jiang MD","doi":"10.1002/cncy.22875","DOIUrl":"10.1002/cncy.22875","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Molecular testing of thyroid nodules is an essential tool to help risk stratify nodules with indeterminate cytology. Although ThyroSeq testing has been around for over a decade, there is a paucity of long-term follow-up data on cytologically indeterminate nodules that are determined to be molecularly negative or low-risk. The objective of this study is to assess the outcomes of nodules with indeterminate cytology (Bethesda III or IV) and negative or low-risk ThyroSeq results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a single academic institution retrospective cohort study. Patients with at least one thyroid nodule sampled with fine-needle aspiration who underwent ThyroSeq testing from 2012 to 2018 and had negative or low-risk ThyroSeq results on a cytologically indeterminate sample (<i>n</i> = 159 patients, 167 nodules) were included in the study. Outcomes include the false-negative rate and negative predictive value of each test version, as well as follow-up length for each nodule.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 159 patients with a mean age of 58 years (7–84 years) included in this study; the majority were female (81.8%). The mean follow-up was 4.0 years. Of 167 nodules, three were found to be malignant on resection (1.8%). The negative predictive value for the entire cohort was 98.2% and it was 89.3% for the surgical series.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ThyroSeq testing has good negative predictive value and can help risk stratify cytologically indeterminate nodules. Routine follow-up allows for safe monitoring of nodules for features suggestive of malignancy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 10","pages":"629-634"},"PeriodicalIF":2.6,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141549354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genotype profile of HPV in ASC-H cytology and histologic follow-up—prevalence, distribution, and risk: A retrospective study of 1414 cases","authors":"Yihua Sun MD,&nbsp;Tiannan Wang MD, PhD,&nbsp;Fangfang Zhong MD,&nbsp;David Starr MD,&nbsp;Xianxu Zeng MD, PhD,&nbsp;Hao Zhang MD,&nbsp;Jianan Xiao MD,&nbsp;Xianrong Zhou MD,&nbsp;Xiang Tao MD, PhD,&nbsp;Chengquan Zhao MD","doi":"10.1002/cncy.22877","DOIUrl":"10.1002/cncy.22877","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>A cytologic diagnosis of <i>atypical squamous cells, cannot exclude high-grade squamous lesion</i> (ASC-H) poses a disproportionately high risk of cervical cancer development. The objective of this study was to analyze type-specific risks by mapping human papillomavirus (HPV) genotypes in ASC-H cytology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In total, 1,048,581 Papanicolaou tests that had ASC-H cytology were retrieved. Concurrent HPV genotyping using proprietary multiplex real-time (MRT) and polymerase chain reaction (PCR) HPV tests and histologic follow-up findings were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 1678 patients who had ASC-H findings (0.16%), 1414 (84.3%) underwent concurrent HPV genotyping (MRT, 857; HPV PCR test, 557). The overall high-risk HPV (hrHPV)-positive rate was 84.4%. Of the 857 MRT cases, 63.9% were infected with a single hrHPV, and 24.4% had multiple genotypes. The most prevalent HPV types were HPV16/52/58/33/31. Lesions that were identified as cervical intraepithelial neoplasia 2 or worse (CIN2+) were detected in 498 of 906 cases (55.0%), including 81 cervical carcinomas (8.9%). The risk of CIN2+ for the composite group of HPV16/52/58/33/31-positive cases was 62.7%, representing 90.7% (264 of 291) of total CIN2+ lesions in ASC-H/hrHPV–positive cases by MRT. CIN2+ lesions were detected in 108 of 142 (76.1%) HPV16-positive and/or HPV18-positive women by the PCR the HPV test. Among 128 hrHPV-negative ASC-H cases by both methods, CIN2+ lesions were identified in 21 of 128 (16.4%), including five cervical carcinomas (3.9%). The sensitivity, specificity, positive predictive value, and negative predictive value for patients in the composite group with HPV16/52/58/33/31 were 88.0%, 40.8%, 62.7%, and 75.0%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Papanicolaou tests classified as ASC-H are associated with a high CIN2+ rate and warrant colposcopy, regardless of HPV status. The extent to which the risk-stratification provided by comprehensive HPV genotyping can inform the management of ASC-H cytology remains to be explored.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 9","pages":"588-598"},"PeriodicalIF":2.6,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22877","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytologic features of differentiated high-grade thyroid carcinoma: A multi-institutional study of 40 cases","authors":"Vanda F. Torous MD,&nbsp;Tikamporn Jitpasutham,&nbsp;Zubair Baloch,&nbsp;Richard L. Cantley,&nbsp;Darcy A. Kerr,&nbsp;Xiaoying Liu,&nbsp;Zahra Maleki MD,&nbsp;Ross Merkin,&nbsp;Vania Nosé,&nbsp;Liron Pantanowitz,&nbsp;Isabella Tondi Resta,&nbsp;Esther D. Rossi MD, PhD,&nbsp;William C. Faquin","doi":"10.1002/cncy.22874","DOIUrl":"10.1002/cncy.22874","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Differentiated high-grade thyroid carcinoma (DHGTC) is recently recognized by the World Health Organization (WHO) as a subgroup of thyroid carcinomas with high-grade features while retaining the architectural and/or cytologic features of well-differentiated follicular–cell-derived tumors. The cytomorphology of DHGTC is not well documented despite potential implications for patient triage and management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The pathology archives of six institutions were searched for cases diagnosed on resection as “high-grade thyroid carcinoma” using WHO criteria. The fine-needle aspiration (FNA) cohort represents a 10-year period (2013–2023); all were reviewed to confirm DHGTC classification. The corresponding FNAs were assessed for 32 cytomorphologic features.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty cases of DHGTC with prior FNA were identified. The mean patient age was 64.2 years. The average lesion size was 4.9 cm, and the majority demonstrated a TI-RADS score of 4 or 5 (95.2%). Three main high-grade subsets of DHGTC based on corresponding histology included papillary thyroid carcinoma (65%), follicular carcinoma (22.5%), and oncocytic carcinoma (12.5%). Over 97% of FNA cases were classified as Bethesda category IV or above. Approximately 25% of DHGTC showed cytologic features that included marked cytologic atypia, increased anisonucleosis, large oval nuclei, mitotic activity, or necrosis (<i>p</i> &lt; .05); 68% of DHGTC cases were associated with high-risk molecular alterations. <i>TERT</i> mutations occurred in 41%, of which 89% of these were associated with a second mutation, usually <i>RAS</i> or <i>BRAF p</i>.V600E.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Cytology has a low sensitivity for DHGTC, although a subset of DHGTCs have cytologic features raising the possibility of a high-grade thyroid carcinoma. Other findings include high-risk molecular changes and clinicopathologic features such as older patient age and larger lesion size.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 8","pages":"525-536"},"PeriodicalIF":2.6,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reimagining the future of cancer clinical trials","authors":"Bryn Nelson PhD,&nbsp;William Faquin MD, PhD","doi":"10.1002/cncy.22837","DOIUrl":"10.1002/cncy.22837","url":null,"abstract":"&lt;p&gt;Oncology is facing a growing disconnect. Decades of advancement in basic research have spurred an unparalleled understanding of the pathology, molecular mechanisms, development, and immunology of cancers—spurring big dreams of personalized therapies and lasting cures. In 2024, however, taking a new anticancer drug from bench to bedside still requires nearly 8 years and $1.5 billion to $2.5 billion according to recent estimates, and the vast majority of efforts end in failure.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Meanwhile, clinical trial enrollment has lagged even at large academic medical centers, in part because information about particular trials often never reaches eligible patients.&lt;/p&gt;&lt;p&gt;New ideas are desperately needed, says Vivek Subbiah, MD, chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. The high cost and failure rate, “combined with the inherited inefficiencies and deficiencies that plague the siloed healthcare ecosystem, has led to a crisis in clinical research and drug development,” he says.&lt;/p&gt;&lt;p&gt;The coronavirus disease 2019 pandemic, interestingly, provided an unexpected opening for experimentation and reconsideration, Dr Subbiah and other experts note. Amid major disruptions to medical infrastructure and drug delivery systems, the US Food and Drug Administration (FDA) and other clinical trial sponsors permitted more flexible designs and a shift toward more patient-centric and intuitive evidence-generating strategies. The drug development community now is pondering whether some allowances could become permanent or least provide a framework for more flexibility in key areas without compromising patient safety.&lt;/p&gt;&lt;p&gt;One big trend is front-loading preclinical assessments and phase 1 trials to ramp up the early indications of a drug’s likelihood of success. Reformers have advocated leaning into the undeniably complex but rapidly expanding power of -omics technology—not just genomics and proteomics but also epigenetics, metabolomics, immunogenomics, and lipidomics—to make better sense of the data. The more granular information could give researchers a jump on understanding a drug’s promise in preclinical and early-phase trials and on identifying which patient subgroups are most likely to benefit. Phase 1 trials, for their part, traditionally have focused primarily on optimal dosage and safety. More recently, however, they also have begun to include demonstrations of a drug’s proof of mechanism or the treatment’s proof of concept.&lt;/p&gt;&lt;p&gt;“This upfront information, and all the information about the molecular portrait of every patient walking in the door with cancer, can enhance efficiency of trials by enrolling patients with a specific biomarker who have a higher likelihood of benefiting from an experimental drug—or any drug for that matter,” Dr Subbiah says.&lt;/p&gt;&lt;p&gt;Advances in precision medicine are adding new layers of complexity to the patient selection process. Clinicians are conducting incr","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 6","pages":"331-332"},"PeriodicalIF":3.4,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22837","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141198781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of different fixatives on immunostaining of lung adenocarcinomas in pleural effusion cell blocks","authors":"Mohammed S. I. Mansour CT, PhD,&nbsp;Louise Pettersson MD, PhD,&nbsp;Tomas Seidal MD, PhD,&nbsp;Ulf Strömberg PhD,&nbsp;Ulrich Mager MD,&nbsp;Lana Ali BSc,&nbsp;Sana Kumbaric BSc,&nbsp;Kim Hejny BSc,&nbsp;Fereshteh Taheri-Eilagh BSc,&nbsp;Joudy Mufti CT, BSc,&nbsp;Dawla Nakdali BSc,&nbsp;Hans Brunnström MD, PhD","doi":"10.1002/cncy.22833","DOIUrl":"10.1002/cncy.22833","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cell blocks (CBs) are widely used for biomarker analyses such as immunostaining. Although immunohistochemistry on formalin-fixed paraffin-embedded tissues is standardized, there are multiple preparation methods and fixatives for cytology. Our objective was to investigate the effect of different common fixatives on the immunoreactivity of pleural effusion CBs with metastatic lung adenocarcinomas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study included 24 malignant pleural effusions from different patients with lung adenocarcinoma. From each case, four identical CBs were fixed in 10% neutral buffered formalin, PreservCyt, CytoLyt, and CytoRich Red (only 17 of the cases), respectively. Samples containing &lt;100 malignant cells were excluded. All CBs were stained with thyroid transcription factor 1 (TTF-1; clones 8G7G3/1 and SPT24), napsin A, claudin 4, CEA, CK7, and epithelial cell adhesion molecule (EpCAM; clones BS14, Ber-Ep4, and MOC-31). The fraction and intensity of stained cells were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the investigated markers, a significant difference in staining proportion was seen for TTF-1 clone 8G7G3/1 and EpCAM clone MOC-31, especially with cases being negative in CytoLyt (33.3% and 83.3% positive, respectively) and PreservCyt (62.5% and 83.3%) whereas being positive in CytoRich Red (76.5% and 94.1%) and formalin (both 95.8%). A significantly weaker intensity of staining was seen for all alcohol-based fixatives compared to formalin for TTF-1 clone 8G7G3/1, napsin A, and EpCAM clone MOC-31, whereas EpCAM clone Ber-Ep4 was significantly weaker only in PreservCyt compared with formalin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Immunocytochemical expression and concordance with formalin-fixed CBs differ depending on the used fixative as well as the antibody and clone, warranting investigation of the reliability of each biomarker for non–formalin-fixed cytology.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 9","pages":"569-579"},"PeriodicalIF":2.6,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22833","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of ultrasensitive RNA in situ hybridization for kappa and lambda light chains assists in the differential diagnosis of B-cell non-Hodgkin and Hodgkin lymphomas in cytopathology practice","authors":"Hatem Kaseb MD, PhD, MPH,&nbsp;Diane Davis Davey MD","doi":"10.1002/cncy.22834","DOIUrl":"10.1002/cncy.22834","url":null,"abstract":"","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 11","pages":"675-677"},"PeriodicalIF":2.6,"publicationDate":"2024-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real-world, observational study","authors":"Tanvi Verma MD,&nbsp;Cody Marshall DO,&nbsp;Kossivi E. Dantey MD,&nbsp;Diane V. Thompson MS,&nbsp;Anna Banizs MD,&nbsp;Sydney D. Finkelstein MD,&nbsp;Joseph DelTondo DO","doi":"10.1002/cncy.22829","DOIUrl":"10.1002/cncy.22829","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Molecular analysis of fine-needle aspiration biopsies (FNAB) improves the diagnostic accuracy of cytologically indeterminate thyroid nodules (ITNs). Recently, the use of MPTXv2 has been shown to further improve the accuracy of risk stratification of ITNs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 338 patient samples with atypia of undetermined significance (<i>n</i> = 258) or follicular neoplasm (<i>n</i> = 80) cytology diagnosis and corresponding surgical outcomes or clinical follow-up, collected between 2016 and 2020 were included [Correction added on 19 June 2024, after first online publication: In the preceding sentence, the <i>n</i> values 260 and 78 have been changed to 258 and 80, respectively.]. All samples underwent multiplatform testing (MPTXv1), which includes an oncogene panel (ThyGeNEXT^®) plus a microRNA risk classifier (ThyraMIR^®). A blinded, secondary analysis was performed to assess the added utility of MPTXv2 (ThyraMIR^®v2). The average length of follow-up for the surveillance group (<i>n</i> = 248) was 30 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sensitivity at moderate threshold was 96% and specificity at positive threshold was 99% for MPTXv2. At 14% disease prevalence, the negative predictive value at the moderate threshold was 99% and the positive predictive value at the positive threshold was 89% for MPTXv2. MPTXv2 had fewer patients classified into the moderate-risk group than MPTXv1, which was statistically significant (<i>p</i> &lt; .001). Using surgical resection, the gold standard for outcomes, MPTXv2 showed a statistically greater area under the curve (<i>p</i> = .028) than MPTXv1, demonstrating greater accuracy for MPTXv2.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Both test versions demonstrated robust performance with low false-positive molecular results. Data suggest that incorporation of MPTXv1, and more recently MPTXv2, into clinical practice within our healthcare network resulted in improved accuracy of ITN risk stratification.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9410,"journal":{"name":"Cancer Cytopathology","volume":"132 9","pages":"556-563"},"PeriodicalIF":2.6,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncy.22829","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}